ABL1 and acute lymphoblastic leukemia: Nine out of 51 CR patientsunderwent allogeneic-HSCT with no significant differences in the proportion of transplanted patients between BCR-ABL1-like and the remaining B-other ALL patients [2/13(15%) vs 7/38 (18%), respectively, P = 1.000].